Archives of Dermatological Research

, Volume 282, Issue 5, pp 311–317 | Cite as

Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional treatment with alpha2-interferon

  • N. Mozzanica
  • A. Cattaneo
  • V. Boneschi
  • L. Brambilla
  • E. Melotti
  • A. F. Finzi
Original Contributions


We investigated the peritumoral and intratumoral immune infiltrate in 6 basal cell carcinomas (BCCs) treated with recombinant alpha2b-interferon. Each BCC was injected intralesionally three times a week for 3 weeks with 1.5×106 IU of interferon per injection (total dose 13.5×106 IU). The immunohistological study was done before the start of interferon therapy and 15 days afterwards, using a series of monoclonal antibodies and an immunocytochemical technique. Before therapy the infiltrate consisted mainly of CD3+ (T) cells, with prevalence of CD4+ (helper/inducer) T cells. The percentage of T cells expressing interleukin-2 receptor (CD25+ cells) was higher in the tumor nests than in the peritumoral infiltrate (20% and 11% respectively). CD1+ (Langerhans) cells and CD14b+ cells (monocytes/macrophages) were present in the peritumoral infiltrate in all cases (9%±5% and 14%±7% respectively). Very few CD56+ (natural killer), CD15+ (granulocytes) and CD20+ (B) cells were observed in the peritumoral infiltrate and none at all in tumor nests. After 15 days of interferon therapy, we observed an increase in peritumoral and intratumoral CD4+ cells. There was a decrease in the number of CD25+ cells and of CD1+ cells in the peritumoral infiltrate. The number of intratumoral CD25+ increased. No variations were seen in CD14b, CD15, CD20, and CD56 positive cells. Eight weeks after completion of therapy, two BCCs were cleared and the remaining four showed clinical and histological improvement. These results may indicate a direct effect of interferon against BCC; in addition the immunohistological findings suggest that intralesional interferon enhances T cell mediated immune response, especially in tumor nests. Interferon may therefore act against BCC as a cytotoxic agent and as an immunomodulator.

Key words

Basal cell carcinoma Alpha2-interferon Immunohistology 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bunn PA, Foon KA, Ihde DC, Dahl MV (1984) Recombinant leukocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101:484–487Google Scholar
  2. 2.
    Bustamonte R, Schmitt D, Pillet C, Thivolet J (1977) Immunoglobulin producing cells in the inflammatory infiltrates in cutaneous tumors. Immunocytologic identification in situ. J Invest Dermatol 68:346–349Google Scholar
  3. 3.
    Clemens MJ, McNurlan MA (1985) Regulation of cell proliferation and differentiation by interferons. Biochem J 226:345–460Google Scholar
  4. 4.
    Cordell JL, Falini B, Erben WN, Ghosh AK, Abdulaziz Z, Macdonald S, Pulford K, Stein H, Mason DY (1984) Immunoenzymatic labeling monoclonal antibodies using immune complex of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32:219–229Google Scholar
  5. 5.
    Creagan ET, Ahmann DL, Green SJ, Tanner DJ (1984) Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 54:2844–2849Google Scholar
  6. 6.
    Dellon AL, Patvin C, Chretien PB, Rogentine CN (1975) The immunobiology of skin cancer. Plast Reconstr Surg 55:341–354Google Scholar
  7. 7.
    De Panfilis G, Colli V, Manfredi G, Misk I, Rima J, Zampetti M, Allegra F (1979) In situ identification of mononuclear cell infiltrating cutaneous carcinoma: an immunohistochemical study. Acta Derm Venereol (Stockh) 59:219–222Google Scholar
  8. 8.
    Eaglstein NF, Hernandez AD, Allen II JE (1982) Lymphocytic response to basal cell carcinoma: in situ identification of functional subsets using monoclonal antibodies. J Dermatol Surg Oncol 8:943–947Google Scholar
  9. 9.
    Greenway HT, Cornell RC, Tanner DJ, Peets E, Bordin GM, Nagi C (1986) Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15:437–443Google Scholar
  10. 10.
    Grob JJ, Collet AM, Munoz MH, Bonerandi JJ (1988) Treatment of large basal cell carcinoma with intralesional interferonalpha2a. Lancet I:878–879Google Scholar
  11. 11.
    Habets JMW, Tank B, Vuzevski VD (1988) The characterization of the mononuclear infiltrate in basal cell carcinoma: a predominantly T cell mediated immune response with minor participation of Leu7+ (natural killer) cells and Leu 14+(B) cells. J Invest Dermatol 90:289–292Google Scholar
  12. 12.
    Habets JMW, Tank B, Vuzevski VD, Stolz E, van Joost T (1989) An absence of human leukocyte antigen-DR and a decreased expression of beta2-microglobulin on tumor cells of basal cell carcinoma: no influence on the peritumoral immunoinfiltrate. J Am Acad Dermatol 20:47–52Google Scholar
  13. 13.
    Herbermann RB, Holden HT (1979) Natural killer cells as antitumor effector cells. J Natl Cancer Inst 62:441–446Google Scholar
  14. 14.
    Kato T, Minagawa T (1981) Enhancement of cytotoxicity of human peripheral blood lymphocytes by interferon. Microbiol Immunol 25:837–845Google Scholar
  15. 15.
    Nakamura M, Mauser T, Pearson GDN, Dalay JM, Gefter ML (1984) Effect of IFN-alpha on the immune response in vivo and on gene expression in vitro. Nature 307:381–383Google Scholar
  16. 16.
    Rios A, Mansell P, Newell G, Hansen RC (1984) The use of lymphoblastoid interferon HV IFN alpha-(Ly) in the treatment of acquired immunodeficiency syndrome (AIDS) related Kaposi's sarcoma (KS). Proc Am Soc Clin Oncol 3:63 (Abstract C-245)Google Scholar
  17. 17.
    Rubenstein M (1982) The structure of human interferons. Biochim Biophys Acta 695:5–16Google Scholar
  18. 18.
    Schaumburg-Lever G (1987) The alkaline phosphatase anti-alkaline phosphatase technique (APAAP) in dermopathology. J Cutan Pathol 14:6–9Google Scholar
  19. 19.
    Smolle J, Soyer HP, Ehall R, Bartenstein S, Kerl H (1986) Langerhans cell density in epithelial skin tumors correlates with epithelial differentiation but not with the peritumoral infiltrate. J Invest Dermatol 87:477–479Google Scholar
  20. 20.
    Synkowski DR, Shuster P, Orlando JC (1985) The immunobiology of basal cell carcinoma: an in situ monoclonal antibody study. Br J Dermatol 113:441–446Google Scholar
  21. 21.
    Viac J, Bustamonte R, Thivolet J (1977) Characterization of mononuclear cells in the inflammatory infiltrates of cutaneous tumors. Br J Dermatol 97:1–10Google Scholar
  22. 22.
    Wickramasinghe L, Hindson TC, Wacks H (1989) Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 20:71–74Google Scholar

Copyright information

© Springer-Verlag 1990

Authors and Affiliations

  • N. Mozzanica
    • 1
  • A. Cattaneo
    • 1
  • V. Boneschi
    • 1
  • L. Brambilla
    • 1
  • E. Melotti
    • 1
  • A. F. Finzi
    • 1
  1. 1.Second Department of DermatologyUniversity of MilanMilanItaly

Personalised recommendations